SCHEMBL9984095

SCHEMBL9984095

CC(C)(C)OC(=O)NC1CCN(c2ccccc2N)CC1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.48
PIM3 Q86V86 1/20 0.48
PIM2 Q9P1W9 1/20 0.48
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
GAA P10253 1/20 0.45
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
USP30 Q70CQ3 1/20 0.41
DRD2 P14416 5/20 0.40
SSTR1 P30872 1/20 0.40
SSTR4 P31391 1/20 0.40
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
DRD3 P35462 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ADRA2C P18825 1/20 0.38
HDAC3 O15379 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3211686 0.85 PIM1 (0.60) PIM1PIM3PIM2KMT2AMEN1
SCHEMBL3211670 0.85 PIM1 (0.60) PIM1PIM3PIM2KMT2AMEN1
SCHEMBL14206408 0.85 PIM1 (0.60) PIM1PIM3PIM2KMT2AMEN1
SCHEMBL9984496 0.84 PIM1 (0.44) PIM1PIM3PIM2KMT2AMEN1
SCHEMBL1271996 0.83 CKS1B (0.55) PIM1PIM3PIM2KMT2AMEN1
SCHEMBL13156657 0.81 MAP4K4 (0.56) PIM1PIM3PIM2KMT2ADRD2
SCHEMBL13156648 0.81 MAP4K4 (0.56) PIM1PIM3PIM2KMT2ADRD2
SCHEMBL4553425 0.81 MAP4K4 (0.56) PIM1PIM3PIM2KMT2ADRD2
SCHEMBL18291318 0.80 CKS1B (0.41) CKS1BSKP1SKP2SSTR1SSTR4
SCHEMBL18291503 0.80 MAP4K4 (0.44) KMT2AMEN1CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME DONG WHA PHARM. CO., LTD. (KR) 2011-12-15 US disclosed
EP-2394993-A2 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Dong Wha Pharm. Co., Ltd. (KR) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME NOS3, PTMS, NOS2 PIM1 2441/4885PIM3 1880/4885PIM2 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.